Navigation Links
BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
Date:11/12/2007

of attack in many MS patients. This is accomplished by the I.V. injection of MBP8298 every six months.

Phase II and long-term follow-up treatment of MS patients with MBP8298, recently published in the European Journal of Neurology showed that MBP8298 safely delayed the median time to disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.

MBP8298 is being developed in three late-stage clinical trials:

- MAESTRO-01: A pivotal phase III trial in Canada and Western Europe

evaluating MBP8298 for the treatment of secondary progressive

multiple sclerosis (SPMS). The trial is a randomized, double-blind

study and is fully recruited with 611 patients.

- MAESTRO-03: A pivotal phase III U.S. trial evaluating MBP8298 for the

treatment of SPMS. The trial is a randomized, double-blind study

enrolling approximately 510 patients.

- MINDSET-01: A phase II trial evaluating MBP8298 for the treatment of

relapsing remitting multiple sclerosis (RRMS). The trial is a

randomized, double-blind study and is fully recruited with 218

patients.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Com
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
7. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
8. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
9. ATS Medical Expands Open Pivot Heart Valve Offerings
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. Globus Medical Announces Record 2nd Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - Portage Biotech ... Securities Exchange: PBT.U), is pleased to announce that ... has added two more  consultants to its team ... PPL-003 uses a new proprietary cell permeable peptide ... its anti-inflammatory cargo into the eye. ...
(Date:9/23/2014)... , September 23, 2014 ... Closed System Transfer     Devices  (CSTD) ... partnership with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading ... Taiwan , China ... the company continues to expand globally, and throughout ...
(Date:9/23/2014)... New York (PRWEB) September 23, 2014 ... from around the globe will convene at ... International Conference, to be held October 26-28 ... in evidence-based research and practice in individualized ... physicians, scientists, researchers, nurses, psychologists, nutritionists, naturopaths, ...
(Date:9/22/2014)... 2014 Pearl's Premium Ultra Low Maintenance ... tolerant grass seed this week with the release of ... coincides with the fact that it is time to ... believe. , As of the date 6/4/13, Pearl's ... by industry experts and the media including: The ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... BRISBANE, Australia and SEATTLE, Feb. 24 Implicit,Bioscience ... antibody IC14 from Eli Lilly and Company. Implicit ... to Lilly. Lilly will also,receive a royalty on ... "Implicit Bioscience brings substantial expertise and passion to ...
... Feb. 24 Nektar Therapeutics,(Nasdaq: NKTR ... fourth quarter and,year ended December 31, 2008. , ... year for Nektar," said Howard W. Robin,President and ... unique polymer,conjugation chemistry platform, we advanced numerous proprietary ...
... proteinTHOUSAND OAKS, Calif., Feb. 24 Bone Biologics, Inc. ... Aragen Bioscience, has completed development of a recombinant cell ... protein. Bone Biologics has been developing the protein as ... years of research in the lab performed by the ...
Cached Biology Technology:Implicit Licenses Clinical Stage Antibody Program From Lilly 2Implicit Licenses Clinical Stage Antibody Program From Lilly 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9Bone Biologics Announces UCB-1 (NELL-1) Bone Growth Protein Production Process With Aragen Biosciences 2
(Date:9/22/2014)... Manufacturing biofuels from food crop by-products such as straw ... work of scientists in the UK and France. ... Research Council (BBSRC) have discovered variant straw plants whose ... biofuels, but which are not significantly smaller or weaker ... ease pressure on global food security as biofuels from ...
(Date:9/22/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers report: The protein-bound ice crystals that ... temperatures warm. , The finding is reported ... of Sciences . , "We discovered what appears ... of antifreeze proteins in Antarctic notothenioid fishes," said ...
(Date:9/22/2014)... of seven institutions in the country selected by ... this year,s BEST Award a $2 million ... most promising biomedical sciences graduate trainees to career ... they have traditionally taken. , The award funds ... Biomedical Scientists (iJOBs) program. It includes courses, seminars, ...
Breaking Biology News(10 mins):Plant variants point the way to improved biofuel production 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... relatively common to come across petrol stations surrounded by houses, ... (UM) have studied the effects of contamination at petrol stations ... in buildings less than 100 metres from the service stations. ... increases the risk of cancer have been recorded at ...
... has been awarded a $2.3 million grant by the ... focusing on developing a novel stem cell based therapy ... studying human induced pluripotent stem (iPS) cells derived from ... in the lab and investigate the role of inflammation ...
... not-so-distant evolutionary past, stress often meant imminent danger, ... of our body,s stress response is to stock-pile ... Unit (MMPU), a collaboration between the European Molecular ... University of Heidelberg Medical Centre, have discovered how ...
Cached Biology News:Petrol stations pollute their immediate surroundings 2Stem cell leader awarded $2.3 million grant for Parkinson's 2Blood-clotting protein linked to cancer and septicemia 2Blood-clotting protein linked to cancer and septicemia 3
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
...
Rabbit polyclonal to JNK1 (phospho T183 + Y185) ( Abpromise for all tested applications). entrezGeneID: 5599 SwissProtID: P45983...
Permeabilization Solution, 5X...
Biology Products: